Related Experiment Video

Updated: Jun 5, 2026

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma

Lisa E S Crose1, Corinne M Linardic

  • 1Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.

Sarcoma
|January 22, 2011
PubMed

Insights

Receptor tyrosine kinases (RTKs) are key targets for rhabdomyosarcoma (RMS) treatment. Targeting RTKs offers promise for developing effective therapies against this childhood cancer.

Area of Science:

  • Pediatric oncology
  • Molecular biology
  • Cancer genetics

Background:

  • Rhabdomyosarcomas (RMSs) are the most common pediatric soft tissue sarcomas.
  • Current treatments for high-risk RMS are inadequate, lacking targeted genetic therapies.
  • Research has identified key molecular pathways driving RMS pathogenesis.

Purpose of the Study:

  • To review receptor tyrosine kinases (RTKs) implicated in RMS tumorigenesis.
  • To discuss the therapeutic potential and challenges of targeting RTKs in RMS.

Main Methods:

  • Literature review of RTK family members in RMS.
  • Analysis of RTK signaling pathways in RMS development.
  • Evaluation of small molecule inhibitors, ligand-neutralizing agents, and monoclonal antibodies for RTK targeting.

Main Results:

  • Several RTK family members are implicated in RMS pathogenesis.
  • RTK activity can be modulated through various therapeutic strategies.
  • Targeting RTKs presents both opportunities and challenges for RMS treatment.

Conclusions:

  • RTKs represent promising druggable targets for RMS therapy.
  • Further research is needed to overcome challenges in RTK-targeted treatment for RMS.
  • Developing effective targeted therapies for RMS remains a critical goal.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...